Mesenchymal Stem Cells
Stem Cell Therapy for ALS
This trial will test the safety and efficacy of delivering MSCs to the CSF of people with ALS every 3 months for a total of 4 injections over 12 months. The goal of the study is to determine if this treatment is safe and can improve the subject's ALS symptoms.
PTC857 for ALS
This trial is testing a new drug called PTC857 to see if it can help people with ALS. Participants will either receive PTC857 or a non-active substance. If they complete the initial treatment, they can continue taking PTC857 for an extended period to further assess its effects.
Stem Cell Therapy
CNS10-NPC-GDNF for ALS
This trial is testing the safety of placing special cells into the brains of ALS patients. These cells release a protein that helps brain cells stay alive and healthy. The study aims to see if this new treatment is safe for people.
Rho Kinase Inhibitor
Rho Kinase Inhibitor for ALS
This trial is testing a new drug called WP-0512 to see if it can help people with ALS. It targets patients who have had ALS symptoms for a few years and meet specific health criteria. The drug aims to slow down the progression of ALS symptoms.
Herbal Medicine
TJ-68 for ALS
This trial is testing if a new drug called TJ-68 is safe and effective for improving muscle cramps in people with ALS. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the drug or the placebo.
Popular Filters
Trials for ALS Patients
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Trials for Brain Stem Stroke Patients
Neurostimulation Device
Implantation of brain-computer interface for communication in ALS, quadriplegia, and Locked In Syndrome
This trial will test a brain-computer interface that consists of platinum grids being implanted in the brain to pick up neural signals. Up to 128 channels will be used to test this interface for six months.
Behavioural Intervention
Neurosleeve for Arm Weakness/Paralysis
This trial is testing the NuroSleeve, a wearable device that helps people with weak or paralyzed arms move them using electrical signals. It is aimed at those who haven't fully recovered with standard therapies. The device detects small muscle movements and uses them to activate the brace and stimulate muscles, helping with arm movement. Electrical stimulation has been explored in various contexts, including improving arm and hand function in individuals with spinal cord injuries and post-stroke patients.
Phase 3 Trials
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Antisense Oligonucleotide
ION363 for ALS
This trial is testing a new drug called ION363 to help people with a specific genetic form of ALS (FUS-ALS). The study will see if the drug can help these patients live longer and maintain their abilities better. Participants will receive the drug for a period of time, then all will get the drug for an extended duration.
Trials With No Placebo
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Neurostimulation Device
Implantation of brain-computer interface for communication in ALS, quadriplegia, and Locked In Syndrome
This trial will test a brain-computer interface that consists of platinum grids being implanted in the brain to pick up neural signals. Up to 128 channels will be used to test this interface for six months.
View More Related Trials
Frequently Asked Questions
Introduction to lou gehrig's disease
What are the top hospitals conducting lou gehrig's disease research?
When it comes to advancing the understanding and treatment of Lou Gehrig's disease, several top hospitals are leading the charge. Massachusetts General Hospital in Boston stands out with an impressive 10 ongoing clinical trials dedicated to this debilitating condition, along with a notable history of 62 completed trials since their first recorded study in 2001. Meanwhile, across the border in Toronto, Sunnybrook Health Sciences Centre is making significant contributions as well. With five active Lou Gehrig's disease trials and a total of 13 studies conducted thus far, this Canadian institution has been at the forefront since initiating their inaugural trial in 2014.
In Jacksonville, Florida, Mayo Clinic is also committed to driving progress against this devastating disease. They currently have five active clinical trials focused on Lou Gehrig's disease and have completed a commendable total of 15 studies since beginning their research journey back in 2003. Similarly dedicated is Emory University in Atlanta, which has been actively involved in Lou Gehrig's disease research since recording its first trial in 2003. With five ongoing clinical tests and a comprehensive record of 19 previous studies conducted at their facilities.
Lastly but by no means least Augusta University are forging ahead with four current clinical trials for those suffering from ALS while they hold attained eight accomplishments through such pioneering investigations themselves; theirs can be traced not too long ago back only until2016.These institutions exemplify unwavering dedication to unraveling the mysteries surrounding Lou Gehrig's disease and finding new therapeutic avenues for patients worldwide.
These tireless efforts toward combatting ALS demonstrate that these hospitals are not only providing hope but also pushing boundaries for medical advancement globally
Which are the best cities for lou gehrig's disease clinical trials?
When it comes to clinical trials for Lou Gehrig's disease, several cities stand out as leaders in research and development. Boston, Massachusetts takes the top spot with 21 active trials focused on investigating treatments like BIIB105, Pridopidine, and Baricitinib. New york, New York follows closely behind with 16 ongoing studies exploring SAR443820, Part D: Open-Label Treatment, and dalfampridine among others. Baltimore, Maryland and Toronto, Ontario both have 15 active trials each examining various treatment options such as Pegcetacoplan (APL-2) and AP-101 respectively. San Francisco rounds off the list with 14 active trials investigating PTC857, Pridopidine, ANX005 alongside other potential breakthroughs in treating Lou Gehrig's disease. These cities offer individuals battling this devastating condition access to cutting-edge clinical trials that hold promise for improved care and better outcomes.
Which are the top treatments for lou gehrig's disease being explored in clinical trials?
Promising treatments are currently being investigated in clinical trials for Lou Gehrig's disease. DNL343, with two active trials and a total of three all-time trials dedicated to this condition since its introduction in 2020, shows potential as a therapeutic option. Another contender is PTC857, which is undergoing one active trial and has one all-time trial for Lou Gehrig's disease listed since 2022. AP-101 also emerges as an important player with one ongoing trial and two historical trials dating back to 2019. These treatments offer hope for advancements in the management of Lou Gehrig's disease, bringing us closer to improved outcomes for patients battling this debilitating condition.
What are the most recent clinical trials for lou gehrig's disease?
Clinical trials offer hope for individuals affected by Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS). Recent studies have introduced promising interventions to combat this challenging condition. DNL343 and ABBV-CLS-7262 are undergoing Phase 2 and Phase 3 trials, demonstrating potential benefits in ALS management. Additionally, CK0803 has shown promise in Phase 1 studies. Furthermore, the investigational drug 18F-OP-801 is being tested through combined Phase 1 and Phase 2 trials as a potential treatment option for ALS patients. These innovative approaches provide renewed optimism for those battling Lou Gehrig's disease, paving the way towards improved care and quality of life.
What lou gehrig's disease clinical trials were recently completed?
Several notable clinical trials for Lou Gehrig's disease have recently reached completion, highlighting significant strides in the search for effective treatments. In December 2020, Merit E. Cudkowicz, MD concluded a trial evaluating Pridopidine as a potential therapeutic option. Preceding this, Amylyx Pharmaceuticals Inc.'s trial investigating AMX0035 closed in November 2020. Additionally, Richard Bedlack, M.D., Ph.D., wrapped up their study on Theracurmin HP in August 2020. The comprehensive efforts of researchers also included trials examining CNM-Au8 and Zilucoplan sponsored by Merit E. Cudkowicz in July 2020 and Verdiperstat sponsored by the same researcher during that month as well.